No CrossRef data available.
Article contents
Authors' reply
Published online by Cambridge University Press: 13 June 2014
Abstract
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Letters to the Editor
- Information
- Copyright
- Copyright © Cambridge University Press 1995
References
1.Alvir, JM, Lieberman, JA. A revaluation of the clinical characteristics of Clozapine-induced agranulocytosis in light of the United States experience. J Clin Psychopharmacol 1994; 14, lex 2501:87–9.Google Scholar
2.Meltzer, HY, Cola, P, Way, L, Thompson, PA, Bastani, B, Davies, MA, Snitz, B. Cost effectiveness of Clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993; 150;11:1630–83.Google ScholarPubMed
3.Murdock, PS , Williamson, J. A danger in making the diagnosis of Parkinson's disease. Lancet 1982; 2:1212–3.CrossRefGoogle Scholar
4.Cassano, GB, Castrogiovanni, P, Conti, L. Sulpiride versus haloperidol in schizophrenia: a double-blind comparative trial. CurrTherRes 1975; 17: 189–201.Google ScholarPubMed
5.Gerlach, J, Behnke, K, Heltberg, J, et al.Sulpride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations. Br J Psychiatry 1985; 147: 283–8.CrossRefGoogle Scholar
6.Friefman, JH. The management of the levodopa psychoses. Clin Neuropharmacol 1991;14:283–95.CrossRefGoogle Scholar
7.Alberts, JL, Francois, F, Josserand, F. Study of side effects reported in patients under dogmatil (in french). Sem Hop 1985; 61: 1351–7.Google Scholar